These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1524140)

  • 1. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge.
    Tacket CO; Binion SB; Bostwick E; Losonsky G; Roy MJ; Edelman R
    Am J Trop Med Hyg; 1992 Sep; 47(3):276-83. PubMed ID: 1524140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
    EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.
    Taylor DN; McKenzie R; Durbin A; Carpenter C; Atzinger CB; Haake R; Bourgeois AL
    Clin Infect Dis; 2006 May; 42(9):1283-8. PubMed ID: 16586388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.
    Kotloff KL; Losonsky GA; Nataro JP; Wasserman SS; Hale TL; Taylor DN; Newland JW; Sadoff JC; Formal SB; Levine MM
    Vaccine; 1995 Apr; 13(5):495-502. PubMed ID: 7639017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes.
    Kärnell A; Sweiha H; Lindberg AA
    Vaccine; 1992; 10(3):167-74. PubMed ID: 1557932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.
    Kotloff KL; Nataro JP; Losonsky GA; Wasserman SS; Hale TL; Taylor DN; Sadoff JC; Levine MM
    Vaccine; 1995 Nov; 13(16):1488-94. PubMed ID: 8578831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys.
    Kärnell A; Cam PD; Verma N; Lindberg AA
    Vaccine; 1993; 11(8):830-6. PubMed ID: 8356844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers.
    Li A; Kärnell A; Huan PT; Cam PD; Minh NB; Trâm LN; Quy NP; Trach DD; Karlsson K; Lindberg G
    Vaccine; 1993; 11(2):180-9. PubMed ID: 8438616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis.
    Phalipon A; Kaufmann M; Michetti P; Cavaillon JM; Huerre M; Sansonetti P; Kraehenbuhl JP
    J Exp Med; 1995 Sep; 182(3):769-78. PubMed ID: 7544397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
    Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM
    Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.
    Simon JK; Wahid R; Maciel M; Picking WL; Kotloff KL; Levine MM; Sztein MB
    Vaccine; 2009 Jan; 27(4):565-72. PubMed ID: 19022324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta).
    Islam D; Ruamsap N; Imerbsin R; Khanijou P; Gonwong S; Wegner MD; McVeigh A; Poly FM; Crawford JM; Swierczewski BE; Kaminski RW; Laird RM
    PLoS One; 2023; 18(12):e0294021. PubMed ID: 38091314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G; Cohen D; Orr N; Markus I; Slepon R; Ashkenazi S; Keisari Y
    J Infect Dis; 1997 May; 175(5):1128-33. PubMed ID: 9129076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.
    Chakraborty S; Harro C; DeNearing B; Bream J; Bauers N; Dally L; Flores J; Van de Verg L; Sack DA; Walker R
    Clin Vaccine Immunol; 2016 Apr; 23(4):315-25. PubMed ID: 26865592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition.
    Mukhopadhaya A; Mahalanabis D; Khanam J; Chakrabarti MK
    Vaccine; 2003 Jun; 21(21-22):3043-50. PubMed ID: 12798648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.
    Wahid R; Simon JK; Picking WL; Kotloff KL; Levine MM; Sztein MB
    Clin Immunol; 2013 Jul; 148(1):35-43. PubMed ID: 23649043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis.
    Chakrabarti MK; Bhattacharya J; Bhattacharya MK; Nair GB; Bhattacharya SK; Mahalanabis D
    Acta Paediatr; 1999 Feb; 88(2):161-5. PubMed ID: 10102148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.
    Coster TS; Hoge CW; VanDeVerg LL; Hartman AB; Oaks EV; Venkatesan MM; Cohen D; Robin G; Fontaine-Thompson A; Sansonetti PJ; Hale TL
    Infect Immun; 1999 Jul; 67(7):3437-43. PubMed ID: 10377124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.